Sökresultat

Filtyp

Din sökning på "julie" gav 5000 sökträffar

Schema MVET10 reviderad 210702

Schema MVET10 reviderad 210702 MILJÖSKYDD MVET10 Preliminärt schema 20210701 Kurs: Miljöskydd MVET10, höstterminen 2021 Kursansvarig: Andrea Hjärne Lärare: BN=Birgitta Nordquist, KD=Katrin Dierschke, LEH=Lars-Erik Harderup, MD=Mats Dahlblom, KA=Karin Adalberth, JL=Jonathan Loive, LS=Lars Siljebratt, FN=Fredrik Nilsson, Sara Edlund Fredholm, TF=Thomas Ferdinandsson, TH=Torbjörn Håkansson, LH=Lennar

https://www.cec.lu.se/sv/sites/cec.lu.se.sv/files/2021-07/Schema%20MVET10%20reviderad%20210702.pdf - 2025-02-10

Arsrapport med hist 2019 final version 191216

Årsrapport 2004 för Enheten för medicinens historia, Medicinska Fakulteten, Lunds universitet 1 Årsrapport 2019 för Enheten för medicinens historia, Medicinska Fakulteten, Lunds universitet Enheten för medicinens historia har under året 2019 fortsatt sin verksamhet som en fristående enhet inom Institutionen för kliniska vetenskaper (IKVL) i Lund (prefekt Mikael Bodelsson, sektion 5 med chef Håkan

https://www.medicinhistoria.lu.se/sites/medicinhistoria.lu.se/files/arsrapport_med_hist_2019_final_version_191216.pdf - 2025-02-10

Jagdeep Singh

Forskare Kontaktinformation E-post: jagdeep [dot] singh [at] cec [dot] lu [dot] se Telefon: +46 46 222 47 42Organisation Centrum för miljö- och klimatvetenskap (CEC) Besöksadress: Ekologihuset, Sölvegatan 37, Lund Rumsnummer: C 354 Hämtställe: 50 WebbplatsJagdeep Singhs profil i Lunds universitets forskningsportalAndra roller Forskare BECC: Biodiversity and Ecosystem services in a Changing Climate

https://www.cec.lu.se/sv/jagdeep-singh - 2025-02-11

Finn Hedefalk

Docent Kontaktinformation E-post: finn [dot] hedefalk [at] ekh [dot] lu [dot] se Telefon: +46 73 816 60 29 Mobil: +46 73 816 60 29Organisation Ekonomisk-historiska institutionen Besöksadress: Scheelevägen 15B, Alfa 1, Lund Rumsnummer: Alfa1:2008 Hämtställe: 10 WebbplatsFinn Hedefalks profil i Lunds universitets forskningsportalAndra roller Forskare Centrum för ekonomisk demografi Publikationer Vis

https://www.ehl.lu.se/finn-hedefalk - 2025-02-11

Elsa Trolle Önnerfors

Universitetslektor Kontaktinformation E-post: elsa [dot] trolle_onnerfors [at] jur [dot] lu [dot] se Telefon: +46 46 222 10 97Organisation Juridiska institutionen Rumsnummer: 332 Hämtställe: 56 WebbplatsElsa Trolle Önnerfors profil i Lunds universitets forskningsportalAndra roller Forskare Rättshistoria Docent Juridiska institutionen Publikationer Visar av publikationer. Sorterade efter år och sen

https://www.jur.lu.se/elsa-trolle-onnerfors - 2025-02-11

Microsoft Word - HILMA 2007-05-30.doc

Microsoft Word - HILMA 2007-05-30.doc HILMA Historiska Institutionen i Lund Meddelar Att… Årgång 32, 2006/07, Nr 12, 2007-05-30 Underlagen till HILMA förvaras i pärmar som står i rum 209, på hyllan ovanför faxen. Där hittar du ytterligare information om seminarier, anställningsvillkor, stipendier och annat samt ansök- ningsblanketter i förekommande fall. De sistnämnda, som är samlade i en separat

https://www.hist.lu.se/fileadmin/_migrated/content_uploads/hilma_vt07_08.pdf - 2025-02-10

Microsoft Word - HILMA 2009-04-dd.doc

Microsoft Word - HILMA 2009-04-dd.doc HILMA Historiska Institutionen i Lund Meddelar Att… Årgång 34, 2008/09, Nr 10, 2009-04-29 Underlagen till HILMA förvaras i pärmar som står i rum 209, på hyllan ovanför faxen. Där hittar du ytterligare information om seminarier, anställningsvillkor, stipendier och annat samt ansök- ningsblanketter i förekommande fall. De sistnämnda, som är samlade i en separat

https://www.hist.lu.se/fileadmin/_migrated/content_uploads/hilma_vt09_06.pdf - 2025-02-10

No title

FÖRHANDLINGSPROTOKOLL ORIGINAL Ärende Löner och allmänna anställningsvillkor Riksavtalet mellan Svensk Scenkonst och Akademikerförbunden avseende anställda vid offentligt finansierade teaterinstitutioner Parter Svensk Scenkonst Akademikerförbunden Datum Den 10/2, 16/2, 8/3, 29-30/3, 3/4, 17-19/4 samt per mail och telefon. Plats Teams samt Svensk Scenkonsts lokaler i Stockholm Närvarande för Arbets

https://www.saco.se/globalassets/lokala-akademikerforeningar/privat/akademikerforbunden-aht/dokument/kollektivavtal/forhandlingsprotokoll-svs-institutionsteateravtalet-2023.pdf - 2025-01-28

Rme-2016-0053

Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14–15 September 2015 483Regen. Med. (2016) 11(5), 483–492 ISSN 1746-0751 part of Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop

https://www.regenerative-neurobiology.lu.se/sites/regenerative-neurobiology.lu.se/files/rme-2016-0053.pdf - 2025-02-10

A novel 33-Gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias

Accurate diagnosis of rare inherited anaemias is challenging, requiring a series of complex and expensive laboratory tests. Targeted next-generation-sequencing (NGS) has been used to investigate these disorders, but the selection of genes on individual panels has been narrow and the validation strategies used have fallen short of the standards required for clinical use. Clinical-grade validation o

Benchmarking sustainability in cities : The role of indicators and future scenarios

Scenarios are a useful tool to help think about and visualise the future and, as such, are utilised by many policymakers and practitioners. Future scenarios have not been used to explore the urban context in much depth, yet have the potential to provide valuable insights into the robustness of decisions being made today in the name of sustainability. As part of a major research project entitled Ur

Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight

Understanding the molecular determinants that underpin the clinical heterogeneity of non-muscle-invasive bladder cancer (NMIBC) is essential for prognostication and therapy development. Stage T1 disease in particular presents a high risk of progression and requires improved understanding. We present a detailed multi-omics study containing gene expression, copy number, and mutational profiles that

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

OBJECTIVE: In a multicenter cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that β-amyloid and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. METHODS: We included 417 patients with DLB (age 45-93 years, 31% women). Positivity on β-amyloid (A+)

Sex differences in associations between APOE ε2 and longitudinal cognitive decline

INTRODUCTION: We examined whether sex modifies the association between APOE ε2 and cognitive decline in two independent samples. METHODS: We used observational data from cognitively unimpaired non-Hispanic White (NHW) and non-Hispanic Black (NHB) adults. Linear mixed models examined interactive associations of APOE genotype (ε2 or ε4 carrier vs. ε3/ε3) and sex on cognitive decline in NHW and NHB p

Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes

In type 2 diabetes (T2D), hepatic insulin resistance is strongly associated with nonalcoholic fatty liver disease (NAFLD). In this study, we hypothesized that the DNA methylome of livers from patients with T2D compared with livers of individuals with normal plasma glucose levels can unveil some mechanism of hepatic insulin resistance that could link to NAFLD. Using DNA methylome and transcriptome

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study

Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR-2, addresses this knowledge gap and reports on data collected from 240 patients with relapsed/refractory